Marijuana UseNCT05324813
Examining Effects of Domain Specific Episodic Future Thinking on Cannabis Use
A study testing Domain-Specific Episodic Future Thinking in people with Marijuana Use and Marijuana Dependence, run by Michael Sofis at 1 site in United States.
Trial summary
The overarching goal of this online study is to compare the efficacy of six (weekly) sessions of Domain-Specific Episodic Future Thinking (DS-EFT) relative an active control condition on improving the ability to value future rewards and reducing cannabis use (grams and days of use), tobacco use, and alcohol use among. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Marijuana Use, Marijuana Dependence, Tobacco Use
- What is being tested?
- Domain-Specific Episodic Future Thinking
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2022to Jul 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- at least 18 or older
- reside in the U.S.
- report wanting to reduce cannabis use (4 or higher on scale of 1-10 with higher scores indicating greater desire to reduce use)
- report using cannabis at least 10 days in the last month
- report using cannabis at least 100 days in their lifetime
- Data quality checks passed
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
AHP Corporate Office
Sudbury, Massachusetts, 01776
Michael Sofis, 412-867-8991, sofismichael2@gmail.com
Michael J. Sofis, PhD
About this study
The overarching goal of this online study is to compare the efficacy of six (weekly) sessions of Domain-Specific Episodic Future Thinking (DS-EFT) relative an active control condition on improving the ability to value future rewards and reducing cannabis use (grams and days of use), tobacco use, and alcohol use among.
- Being tested
- Domain-Specific Episodic Future Thinking
- Medical subject headings
- Marijuana Use, Marijuana Abuse, Tobacco Use, Alcohol Drinking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Domain-Specific Episodic Future ThinkingBehavioural
Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
| Study group | Role | What they receive |
|---|---|---|
| Domain-Specific Episodic Future Thinking | Experimental | Not described Receives: Behavioral: Domain-Specific Episodic Future Thinking |
| Episodic Recent Thinking Control Condition | Active comparator | Not described Receives: Behavioral: Domain-Specific Episodic Future Thinking |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of cannabis use grams
Measured: 1-week follow-up
Number of cannabis use days
Measured: 1-week follow-up
Secondary outcomes (5)
Number of tobacco use days
Measured: 1-week follow-up
Number of alcohol use days
Measured: 1-week follow-up
Number of tobacco use times
Measured: 1-week follow-up
Number of alcoholic drinks
Measured: 1-week follow-up
Rate of delay discounting
5-trial adjusting delay discounting task
Measured: 1-week follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2022
- Study startApr 2022 (estimated)
- Primary completionJul 2022 (estimated)
- Study completionJul 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Marijuana UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Michael Sofis
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Dartmouth College
- Responsible party
- Sponsor-investigator, Michael Sofis, Advocates for Human Potential
- Investigators
- Michael J Sofis, PhD, Principal investigator, AHP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05324813
- Sponsor's protocol ID
- 7420
- Status last verified
- Apr 2022
- First submitted
- 16 Mar 2022
- Last updated
- 12 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 12 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Examining Effects of Domain Specific Episodic Future Thinking on Cannabis Use
- ClinicalTrials.gov ID
- NCT05324813
- Acronym / sponsor ID
- 7420
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Michael SofisIndustry (pharma, biotech, devices)
- Collaborators
- Dartmouth College
- Study start
- Apr 2022 (estimated)
- Primary completion
- Jul 2022 (estimated)
- Study completion
- Jul 2022 (estimated)
- First posted
- 12 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overarching goal of this online study is to compare the efficacy of six (weekly) sessions of Domain-Specific Episodic Future Thinking (DS-EFT) relative an active control condition on improving the ability to value future rewards and reducing cannabis use (grams and days of use), tobacco use, and alcohol use among.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Domain-Specific Episodic Future Thinking | Experimental | Behavioral: Domain-Specific Episodic Future Thinking |
| Episodic Recent Thinking Control Condition | Active comparator | Behavioral: Domain-Specific Episodic Future Thinking |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- at least 18 or older
- reside in the U.S.
- report wanting to reduce cannabis use (4 or higher on scale of 1-10 with higher scores indicating greater desire to reduce use)
- report using cannabis at least 10 days in the last month
- report using cannabis at least 100 days in their lifetime
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Domain-Specific Episodic Future ThinkingIndividualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains. | Behavioural | Domain-Specific Episodic Future Thinking, Episodic Recent Thinking Control Condition |
Primary outcome
Number of cannabis use grams
Time frame: 1-week follow-up
Number of cannabis use days
Time frame: 1-week follow-up
5 secondary outcomes
Number of tobacco use days
Time frame: 1-week follow-up
Number of alcohol use days
Time frame: 1-week follow-up
Number of tobacco use times
Time frame: 1-week follow-up
Number of alcoholic drinks
Time frame: 1-week follow-up
Rate of delay discounting
Time frame: 1-week follow-up
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Apr 2022.
- Individual participant dataSharing planned: Yes
Related trials for Marijuana Use
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael J Sofis, PhD principal investigator
AHP
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Domain-Specific Episodic Future Thinking in people with Marijuana Use and Marijuana Dependence, run by Michael Sofis at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Michael J Sofis, PhD (14128678991, msofis@ahpnet.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of cannabis use grams (time frame: 1-week follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Apr 2022.